Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae

doi:10.1093/jac/44.4.533

This Article

	Full Text
	FREE Full Text (PDF)
	Alert me when this article is cited
	Alert me if a correction is posted

Services

	Email this article to a friend
	Similar articles in this journal
	Similar articles in ISI Web of Science
	Similar articles in PubMed
	Alert me to new issues of the journal
	Add to My Personal Archive
	Download to citation manager
	Search for citing articles in: ISI Web of Science (13)
	Request Permissions
	Disclaimer

Google Scholar

	Articles by Onodera, Y.
	Articles by Sato, K.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Onodera, Y.
	Articles by Sato, K.

Social Bookmarking

	What's this?

Journal of Antimicrobial Chemotherapy (1999) 44, 533-536
© 1999 The British Society for Antimicrobial Chemotherapy

Brief report

Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae

Yoshikuni Onodera^*, Yoko Uchida, Mayumi Tanaka and Kenichi Sato

New Product Research Laboratories I, Daiichi Pharmaceutical Co., Ltd, 16-13, Kitakasai 1-Chome, Edogawa-ku, Tokyo 134-8630, Japan

The in-vitro inhibitory activities of sitafloxacin (DU-6859a)and other quinolones against Streptococcus pneumoniae DNA gyraseand topoisomerase IV were measured. IC₅₀s of levofloxacin, ciprofloxacin,sparfloxacin and tosufloxacin against DNA gyrase were almostthree to 12 times higher than those against topoisomerase IV.On the other hand, sitafloxacin showed dual inhibitory activityagainst both enzymes and its IC₅₀s were the lowest among thoseof the quinolones tested. These results suggest that sitafloxacinis an effective agent against pneumococcal infections and thatthe incidence of drug-resistant mutants is low.

^* Tel: +81-3-36890-0151; Fax: +81-3-5696-8344; E-mail: onode90j{at}daiichipharm.co.jp

Add to CiteULike CiteULike Add to Connotea Connotea Add to Del.icio.us Del.icio.us What's this?

This article has been cited by other articles:

R. Okumura, T. Hirata, Y. Onodera, K. Hoshino, T. Otani, and T. Yamamoto
Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae
J. Antimicrob. Chemother., July 1, 2008; 62(1): 98 - 104.
[Abstract] [Full Text] [PDF]

H. J. Smith, K. A. Nichol, D. J. Hoban, and G. G. Zhanel
Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims
J. Antimicrob. Chemother., June 1, 2002; 49(6): 893 - 895.
[Full Text] [PDF]

G. Yague, J. E. Morris, X.-S. Pan, K. A. Gould, and L. M. Fisher
Cleavable-Complex Formation by Wild-Type and Quinolone-Resistant Streptococcus pneumoniae Type II Topoisomerases Mediated by Gemifloxacin and Other Fluoroquinolones
Antimicrob. Agents Chemother., February 1, 2002; 46(2): 413 - 419.
[Abstract] [Full Text] [PDF]

J. E. Morris, X.-S. Pan, and L. M. Fisher
Grepafloxacin, a Dimethyl Derivative of Ciprofloxacin, Acts Preferentially through Gyrase in Streptococcus pneumoniae: Role of the C-5 Group in Target Specificity
Antimicrob. Agents Chemother., February 1, 2002; 46(2): 582 - 585.
[Abstract] [Full Text] [PDF]

M. Takei, H. Fukuda, R. Kishii, and M. Hosaka
Target Preference of 15 Quinolones against Staphylococcus aureus, Based on Antibacterial Activities and Target Inhibition
Antimicrob. Agents Chemother., December 1, 2001; 45(12): 3544 - 3547.
[Abstract] [Full Text] [PDF]

H. Fukuda, R. Kishii, M. Takei, and M. Hosaka
Contributions of the 8-Methoxy Group of Gatifloxacin to Resistance Selectivity, Target Preference, and Antibacterial Activity against Streptococcus pneumoniae
Antimicrob. Agents Chemother., June 1, 2001; 45(6): 1649 - 1653.
[Abstract] [Full Text]

G. Ackermann, Y. J. Tang, A. C. Rodloff, J. Silva Jr, S. H. Cohen, and P. Heisig
In vitro activity of sitafloxacin against Clostridium difficile
J. Antimicrob. Chemother., May 1, 2001; 47(5): 722 - 724.
[Full Text] [PDF]

				H. J. Smith, K. A. Nichol, D. J. Hoban, and G. G. Zhanel Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims J. Antimicrob. Chemother., June 1, 2002; 49(6): 893 - 895. [Full Text] [PDF]

				G. Yague, J. E. Morris, X.-S. Pan, K. A. Gould, and L. M. Fisher Cleavable-Complex Formation by Wild-Type and Quinolone-Resistant Streptococcus pneumoniae Type II Topoisomerases Mediated by Gemifloxacin and Other Fluoroquinolones Antimicrob. Agents Chemother., February 1, 2002; 46(2): 413 - 419. [Abstract] [Full Text] [PDF]

				J. E. Morris, X.-S. Pan, and L. M. Fisher Grepafloxacin, a Dimethyl Derivative of Ciprofloxacin, Acts Preferentially through Gyrase in Streptococcus pneumoniae: Role of the C-5 Group in Target Specificity Antimicrob. Agents Chemother., February 1, 2002; 46(2): 582 - 585. [Abstract] [Full Text] [PDF]

				M. Takei, H. Fukuda, R. Kishii, and M. Hosaka Target Preference of 15 Quinolones against Staphylococcus aureus, Based on Antibacterial Activities and Target Inhibition Antimicrob. Agents Chemother., December 1, 2001; 45(12): 3544 - 3547. [Abstract] [Full Text] [PDF]

				H. Fukuda, R. Kishii, M. Takei, and M. Hosaka Contributions of the 8-Methoxy Group of Gatifloxacin to Resistance Selectivity, Target Preference, and Antibacterial Activity against Streptococcus pneumoniae Antimicrob. Agents Chemother., June 1, 2001; 45(6): 1649 - 1653. [Abstract] [Full Text]

				G. Ackermann, Y. J. Tang, A. C. Rodloff, J. Silva Jr, S. H. Cohen, and P. Heisig In vitro activity of sitafloxacin against Clostridium difficile J. Antimicrob. Chemother., May 1, 2001; 47(5): 722 - 724. [Full Text] [PDF]